Town & Country Bank & Trust CO dba First Bankers Trust CO Reduces Stock Position in Zoetis Inc. $ZTS

Town & Country Bank & Trust CO dba First Bankers Trust CO decreased its position in Zoetis Inc. (NYSE:ZTS) by 60.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 7,493 shares of the company’s stock after selling 11,272 shares during the quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO’s holdings in Zoetis were worth $943,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of ZTS. Summit Place Financial Advisors LLC raised its position in shares of Zoetis by 0.4% in the third quarter. Summit Place Financial Advisors LLC now owns 19,369 shares of the company’s stock valued at $2,834,000 after buying an additional 76 shares during the last quarter. First County Bank CT grew its stake in Zoetis by 5.4% in the 3rd quarter. First County Bank CT now owns 1,535 shares of the company’s stock worth $225,000 after acquiring an additional 79 shares during the period. CWA Asset Management Group LLC grew its stake in Zoetis by 1.1% in the 3rd quarter. CWA Asset Management Group LLC now owns 7,236 shares of the company’s stock worth $1,059,000 after acquiring an additional 80 shares during the period. YANKCOM Partnership raised its holdings in Zoetis by 3.5% in the 4th quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock valued at $302,000 after acquiring an additional 81 shares during the last quarter. Finally, Balefire LLC raised its holdings in Zoetis by 3.5% in the 3rd quarter. Balefire LLC now owns 2,463 shares of the company’s stock valued at $360,000 after acquiring an additional 84 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Trading Down 0.1%

Shares of ZTS opened at $117.83 on Friday. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The firm has a market capitalization of $49.74 billion, a P/E ratio of 19.57, a price-to-earnings-growth ratio of 1.80 and a beta of 0.98. The stock’s fifty day simple moving average is $122.71 and its 200 day simple moving average is $128.09. Zoetis Inc. has a twelve month low of $113.29 and a twelve month high of $172.23.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The firm had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio is 35.22%.

Analysts Set New Price Targets

Several research firms have recently issued reports on ZTS. UBS Group set a $136.00 price objective on Zoetis in a report on Thursday, January 29th. Wall Street Zen upgraded Zoetis from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Barclays began coverage on Zoetis in a research note on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price target on the stock. The Goldman Sachs Group raised shares of Zoetis to a “buy” rating in a research note on Monday, December 15th. Finally, Weiss Ratings cut shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. Six research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.